Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

Video

» Interview

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

May 4, 2022

Video

» Interview

ACC 2022: One-year Results of the Clasp TR Study: Transcatheter Treatment of Tricuspid Regurgitation

April 3, 2022

Video

» Interview

ACC 2022: Insights from the CoreValve US Pivotal and SURTAVI Trials: Five-Year Incidence, Timing And Predictors of Hemodynamic Valve Deterioration ff Transcatheter snd Surgical Aortic Bioprostheses

April 3, 2022

Advertisement

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

What’s Going to Be Hot at ACC 2022, In Person or Virtual

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

ACC 2022: One-year Results of the Clasp TR Study: Transcatheter Treatment of Tricuspid Regurgitation

ACC 2022: Insights from the CoreValve US Pivotal and SURTAVI Trials: Five-Year Incidence, Timing And Predictors of Hemodynamic Valve Deterioration ff Transcatheter snd Surgical Aortic Bioprostheses

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content